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Insights From OCT*Nieves Gonzalo, MD, PHD,y George Dangas, MD, PHD,z Borja Ibanez, MD, PHDyxSEE PAGE 2343V ascular response after coronary angioplastyvaries according to the technique. Acuteresponse after balloon angioplasty is charac-
terized by luminal gain in most cases, although
dissection can occur during the procedure, putting
coronary artery patency at risk. Arterial “elastic
recoil” sometimes follows this acute luminal gain,
resulting in some degree of restenosis.
Bare-metal stents represented a great advance
because they overcame these 2 main limitations of
balloon angioplasty. However, vascular damage
created by bare-metal stent implantation can result in
intense tissue proliferation around the struts, leading
to another form of restenosis: proliferative rather than
mechanical recoil. Drug-eluting stents (DES) were
developed to overcome this limitation by incorpo-
rating antiproliferative drugs. First-generation DES
changed the post-stenting healing process; however,
the lack of coverage of a substantial amount of DES
struts was shown to contribute substantially to stent
thrombosis (1).
Within the past few years, it has been recognized
that the tissue covering stent struts can undergo
changes resembling the atherosclerotic process,
something known as post-stent neoatherosclerosis (2).
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disclose.coherence tomography (OCT), have been funda-
mental to our understanding of this phenomenon in
living patients (3). There has been intense interest in
developing a device to induce a more “natural”
healing of the post-stented vessel. In this regard,
drug-eluting bioresorbable vascular scaffolds (BVS)
have been proposed because of their ability to pro-
vide mechanical scaffolding during the healing pro-
cess only to disappear afterward, which allows
recovery of vessel functionality.In this issue of the Journal, Karanasos et al. (4)
report a long-term OCT evaluation of the vascular
response after ﬁrst-generation BVS implantation. The
study provides a detailed analysis of 8 patients from
cohort A of the ABSORB (A bioabsorbable everolimus-
eluting coronary stent system) study who were
evaluated with OCT 5 years after BVS implantation.
Main ﬁndings include complete device resorption
with no discernible struts, a progressive vessel lumen
enlargement, presence of a signal-rich layer of tissue
around the lumen, and patency of all small side
branches initially “jailed” by the scaffold. The pre-
sent report is important because the performance of
long-term follow-up in asymptomatic subjects with
invasive imaging modalities after BVS implantation is
complicated; it is difﬁcult to envision larger cohorts
with such a long follow-up with OCT.
Two-year follow-up of cohort A demonstrated a
signiﬁcant reduction (34%) in the OCT-discernible
number of struts (5). This new report further shows
complete resorption, with no struts visible at 5 years.
The lumen enlargement observed by these in-
vestigators conﬁrms the trend seen in the 2-year data.
The late lumen enlargement seen also appeared to be
associated with late positive remodeling of a vessel
that was not caged by a stent and by plaque
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ultrasound data. Despite being consistent with pre-
vious reports using different imaging modalities (6),
the OCT data relating to luminal dimensions in this
study should be considered cautiously because the
OCT system and acquisition technique used at base-
line and initial follow-ups differed from the one used
at 5-year follow-up, which possibly inﬂuenced the
results (7).
The most exciting data presented by Karanasos
et al. (4) relate to the pattern of vessel healing 5 years
after BVS implantation. The systematic appearance of
a signal-rich layer, showing a continuum with the
native intimal layer (together forming a “neo-
plaque”), suggests that a BVS implant can produce a
favorable tissue response. The presence of a thin
ﬁbrous cap has been consistently associated with
plaque vulnerability; vascular reaction after stent
implantation includes ﬁbrous cap thickening, which
suggests that “plaque passivation” happens after
stenting. In this regard, BVS could offer unique ad-
vantages over metallic scaffolds, because the healing
process appears to incorporate initial generation of a
new ﬁbrous cap and subsequent scaffold dissolution,
leaving an uncaged coronary segment (5).
We must acknowledge several limitations of the
present study. Its clearest drawback is the extremely
small sample size: 8 patients. As the authors recog-
nize, any conclusion from a study with such a limited
sample size is hypothesis generating at best. Addi-
tionally, the highly selected study population most
probably does not represent the real-life population
currently receiving these scaffolds. Importantly, with
no information about plaque characteristics before
BVS implantation, any conclusion about the device’s
behavior when implanted over plaques with vulner-
able features remains speculative.
It has been demonstrated that the healing response
is determined by the underlying plaque characteris-
tics, with evidence showing that stents implanted in
patients with acute coronary syndromes (ACS) have
less tissue coverage at follow-up, probably related to
strut apposition over a necrotic core and thrombus
inﬂuence on drug distribution (1,8). All the long-term
beneﬁts claimed to be associated with BVS implan-
tation (signal-rich layer followed by neoplaque, unc-
aged artery, and so on) seem to ﬁt perfectly with the
needs of some patients presenting with ACS. Unfor-
tunately, the present study did not include ACS
patients, who are more prone to have plaques with
vulnerable characteristics. Therefore, the application
of the present ﬁndings to a wider population with a
more “vulnerable” phenotype is an exercise of belief.
Finally, the fact that “only” 8 of the 14 living patientsoriginally enrolled underwent 5-year follow-up might
represent a selection bias.
The signal-rich layer of tissue separating the pla-
que from the lumen is claimed as an imaging surro-
gate of favorable vascular healing, but in reality, it
simply reﬂects a thicker barrier between the plaque
core and the bloodstream with no struts embedded.
We have no evidence that this type of tissue response
exerts a clinically relevant protective role. The sta-
bility of the ﬁbrous cap may depend not only on its
thickness but also on its collagen content and orga-
nization; these parameters should be evaluated in
the signal-rich layer in future studies. The lack of
neoatherosclerosis in the signal-rich layer is also
mentioned as an advantage over metallic stents, but
the authors provide no serial data regarding the
evolution over time of signal-rich layer thickness and
plaque characteristics. Therefore, no deﬁnite con-
clusions about neoatherosclerosis formation in the
tissue originally covering the scaffold can be drawn.
In this regard, we want to highlight a different unfa-
vorable healing response (plaque progression, cap
thinning, and thrombus formation) in the scaffolded
segment in 1 patient; in such a small population, it
clouds the conclusion that BVS implantation results
in long-term, favorable healing. The small sample size
precludes a real perspective on this phenomenon.
While we await future studies, the already demon-
strated recovery of endothelial function of the tissue
overlying the scaffold shown in patients 2 years
after BVS implantation (9) supports the hypothesis of
favorable healing.
Another aspect not yet investigated is the impact of
the bioabsorbable scaffolds on bifurcation lesions. In
fact, bifurcation lesion was an exclusion criterion in
the present study, yet this abundant type of lesion
has been difﬁcult to target with metallic stents that
usually compromise (“jail”) the side branch. The
patency of all small side branches initially jailed by
the scaffold in the present study is the closest infor-
mation in this regard, albeit these cannot be consid-
ered true bifurcations (from the interventional
perspective). The 3-dimensional evaluation provided
a comprehensive way of approaching side-branch
analysis and demonstrated patency of the ostium
with thinning of the neointimal bridges initially
formed. No explanation was provided for this phe-
nomenon, but future studies evaluating the relation
with vessel biomechanics would be of great interest.
The potential for disappearance of the jailing struts
over time would intuitively beneﬁt the treated ves-
sels and dependent myocardium.
Another relevant aspect that deserves mention is
that the device used in cohort A (BVS 1.0) is different
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latter shows a markedly higher initial mechanical
stability and longer resorption time. We cannot
envision a different healing pattern with the new BVS
scaffold (10), but again, this must be proved. Future
studies with the current device in a wider and less
selected population and in comparison with new-
generation drug-eluting stent are needed to conﬁrm
the premises here proposed.
In summary, the report by Karanasos et al. (4)
is original and of great scientiﬁc relevance inconstructing the ﬁeld of evidence concerning these
new devices that are emerging as an alternative to
metallic stents. Yet the data presented here must be
taken as hypothesis generating.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Borja Ibanez, Centro Nacional de Investigaciones
Cardiovasculares (CNIC), Imaging, Atherothrombosis,
and Epidemiology Department, Calle Melchor Fer-
nández Almagro 3, 28029 Madrid, Spain. E-mail:
bibanez@cnic.es.RE F E RENCE S1. Nakazawa G, Finn AV, Joner M, et al. Delayed
arterial healing and increased late stent throm-
bosis at culprit sites after drug-eluting stent
placement for acute myocardial infarction pa-
tients: an autopsy study. Circulation 2008;118:
1138–45.
2. Nakazawa G, Otsuka F, Nakano M, et al. The
pathology of neoatherosclerosis in human coro-
nary implants: bare-metal and drug-eluting
stents. J Am Coll Cardiol 2011;57:1314–22.
3. Kang SJ, Mintz GS, Akasaka T, et al. Optical
coherence tomographic analysis of in-stent neo-
atherosclerosis after drug-eluting stent implanta-
tion. Circulation 2011;123:2954–63.
4. Karanasos A, Simsek C, Gnanadesigan M, et al.
OCT assessment of the long-term vascular healing
response 5 years after everolimus-eluting bio-
resorbable vascular scaffold. J Am Coll Cardiol
2014;64:2343–56.
5. Serruys PW, Ormiston JA, Onuma Y, et al.
A bioabsorbable everolimus-eluting coronarystent system (ABSORB): 2-year outcomes and re-
sults from multiple imaging methods. Lancet
2009;373:897–910.
6. Nieman K, Serruys PW, Onuma Y, et al. Multi-
slice computed tomography angiography for
noninvasive assessment of the 18-month perfor-
mance of a novel radiolucent bioresorbable
vascular scaffolding device: the ABSORB trial (a
clinical evaluation of the bioabsorbable everolimus
eluting coronary stent system in the treatment of
patients with de novo native coronary artery le-
sions). J Am Coll Cardiol 2013;62:1813–4.
7. Gonzalo N, Serruys PW, García-García HM, et al.
Quantitative ex vivo and in vivo comparison of
lumen dimensions measured by optical coherence
tomography and intravascular ultrasound in human
coronary arteries. RevEspCardiol 2009;62:615–24.
8. Gonzalo N, Barlis P, Serruys PW, et al. Incom-
plete stent apposition and delayed tissue coverage
are more frequent in drug-eluting stents implan-
ted during primary percutaneous coronaryintervention for ST-segment elevation myocardial
infarction than in drug-eluting stents implanted
for stable/unstable angina: insights from optical
coherence tomography. J Am Coll Cardiol Intv
2009;2:445–52.
9. Brugaletta S, Heo JH, Garcia-Garcia HM, et al.
Endothelial-dependent vasomotion in a coronary
segment treated by ABSORB everolimus-eluting
bioresorbable vascular scaffold system is related
to plaque composition at the time of bioresorption
of the polymer: indirect ﬁnding of vascular
reparative therapy? Eur Heart J 2012;33:1325–33.
10. Serruys PW, Onuma Y, Dudek D, et al. Evalu-
ation of the second generation of a bioresorbable
everolimus-eluting vascular scaffold for the
treatment of de novo coronary artery stenosis: 12-
month clinical and imaging outcomes. J Am Coll
Cardiol 2011;58:1578–88.
KEY WORDS percutaneous coronary
intervention, plaque, stents
